Overview
GeneTech Innovations is at the forefront of biotechnology, dedicated to developing cutting-edge gene therapy treatments for rare genetic disorders. Our proprietary platform leverages CRISPR technology to edit genes with high precision, enabling us to address diseases that currently lack effective treatments. We have successfully completed our initial preclinical studies, showing promising results in targeted gene modifications that can reverse disease symptoms. With $2 million in funding, we aim to accelerate our clinical trial processes and expand our research capabilities. Our team has already formed partnerships with leading academic institutions, providing us the advantage of utilizing their facilities and expert knowledge. We have conducted research that has demonstrated significant efficacy in animal models, and we are now poised to progress into human trials. The demand for effective gene therapies has never been higher, with the global gene therapy market projected to exceed $30 billion by 2026. This investment will not only help us validate our technology in clinical settings but also position us as leaders in an emerging field. We believe that with the right funding and s…
Use of funds
The requested $2 million will be allocated as follows:
- Clinical Trials: $1.2 million for initiating Phase 1 human trials.
- R&D Expansion: $500,000 to enhance our lab facilities and hire additional research staff.
- Regulatory Compliance: $300,000 for obtaining necessary approvals and ensuring compliance with FDA regulations.
Open case
Open this case to get the detailed business plan and direct contact with the founder or seeker.